CONTACT
ABOUT ABBOTT
cardiovascular
MY ACCOUNT

Structural Interventions

Congenital Heart Defects

The Amplatzer portfolio of structural intervention occluders provides minimally invasive treatment options for the closure of congenital heart defects and for stroke risk reduction. The closure procedures are performed through a transcatheter approach, which prevents the need for open heart surgery and enables faster recovery times.

Structural Interventions: Congenital Heart Defects

Amplatzer™ Duct Occluders
 

The Amplatzer Family of Duct Occluders offers an extensive line of devices and a simple treatment option for the closure of patent ductus arteriosus (PDA). Amplatzer™ Duct Occluders are designed to occlude PDAs of various shapes and sizes. With an easy-to-perform deployment procedure, the implanting physician can be confident in placing the device with precision.

Amplatzer PDA Duct Occluders

Amplatzer™ Septal Occluders
 

Amplatzer™ Septal Occluders are the standard of care for minimally invasive atrial septal defect (ASD) closure.1,2 These double-disc occluders are comprised of nitinol mesh and polyester material. They are designed to securely appose the septal wall on each side of the defect and create a platform for tissue in-growth after implantation.

Amplatzer Septal Occluders

Amplatzer™ Muscular VSD Occluders

Ventricular septal defects (VSD) are the most commonly found congenital heart defect.3 One subtype of these defects is muscular VSD. If left untreated it can lead to pulmonary hypertension and/or congestive heart failure.4 The Amplatzer™ Muscular VSD Occluders are designed for complete closure of these type of defects.

Amplatzer Muscular VSD Occluder

References

  1. Kashour TS, Latroche B, Elhoury ME, et al. Successful percutaneous closure of a secundum atrial septal defect through femoral approach in a patient with interrupted inferior vena cava. Congenit Heart Dis. 2010;5:620–623.
  2. Tadros VX, Asgar AW. Transcatheter closure of atrial septal defects: an update on ASD occlusion devices. Card Interv Today. 2016; March-April.
  3. Hoffman J, Kaplan S. The incidence of congential heart disease. J Am Coll Cardiol. 2002;39(12):1890-1900.
  4. Data on file at Abbott.

MAT-2304769 v1.0

 

Abbott Logo

Information contained herein for distribution in Australia and New Zealand only.

CAUTION: These products are intended for use by or under the direction of a physician. Prior to use, reference the Instructions for Use, inside the product carton (when available) or online for more detailed information on Indications, Contraindications, Warnings, Precautions and Adverse Events. Illustrations are artist's representations only and should not be considered as engineering drawings or photographs.

Unless otherwise specified, all product names appearing in this Internet site are trademarks owned by or licensed to Abbott, its subsidiaries or affiliates. No use of any Abbott trademark, trade name, or trade dress in this site may be made without the prior written authorization of Abbott, except to identify the product or services of the company. ™ Indicates a trademark of the Abbott group of companies. ‡ Indicates a third party trademark, which is property of its respective owner.

Abbott Vascular division of Abbott Medical New Zealand Ltd, Grd Flr, Bldg. D, 4 Pacific Rise Mt Wellington, Auckland 1060 Tel: 0800 827 285

Abbott Vascular division of Abbott Medical Australia Pty Ltd, 299 Lane Cove Road, Macquarie Park NSW 2113, Tel: 1800 550 939

© 2024 Abbott. All Rights Reserved.

MAT-2105201 v6.0

Disclaimer

You are about to enter an Abbott country or region specific website.

Please be aware that the website you have requested is intended for the residents of a particular country or countries, as noted on that site. As a result, the site may contain information on pharmaceuticals, medical devices and other products or uses of those products that are not approved in other countries or regions

 

Do you wish to continue and enter this website?

 MAT-2408064 V1.0